Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) and the immunosuppressant drug cyclosporine (CSA) are concurrently administered in arthritis. Here, we investigated whether diclofenac (non-selective inhibitor of cyclooxygenase-1 and 2, COX-1/COX-2), celecoxib (selective COX-2 inhibitor) or SC560 (selective COX-1 inhibitor) interact variably with haemodynamic effects of CSA in conscious female rats. Changes caused by CSA (10 mg/kg i.v.) in blood pressure (BP), heart rate (HR), HR variability (HRV) and myocardial contractility were assessed in the absence and presence of individual NSAIDs (10 mg/kg each). Compared with vehicle values, CSA caused immediate and sustained (i) increases in BP and decreases in pulse pressure index (PPI) and HR, (ii) elevations in left ventricular (LV) contractility (dP/dt max ) and isovolumic relaxation constant (Τau) and (iii) increases in the time-and frequency-domain indices of HRV and shifted the cardiac sympathovagal balance towards parasympathetic dominance. CSA hypertension was abolished in rats pre-treated with celecoxib and intensified in the presence of diclofenac or SC560. Alternatively, the CSA-evoked decreases in PPI, increases in HRV indices and cardiac parasympathetic dominance were blunted by celecoxib in contrast to no effect for diclofenac or SC560. Similarly, celecoxib, but not other NSAIDs, eliminated the elevated LV contractility (dP/dt max ) and isovolumic relaxation constant (Τau, s), which reflect cardiac systolic and diastolic function, respectively, that accompanied the CSA-induced pressure load. The data underscore the preferential capacity of selective COX-2 inhibition by celecoxib to mitigate CSA hypertension and consequent alterations in cardiac performance and autonomic balance. By contrast, CSA effects are preserved or even exacerbated after COX-1 inhibition.
Despite the clinical importance of CSA as an immunosuppressant in organ transplantation and in the management of autoimmune disease, it causes serious cardiovascular adverse effects such as hypertension. The hypertensive effect of CSA has been attributed to (i) up-regulation of endothelin [1, 2] , thromboxane [3] , sympathetic [4] and angiotensin activity [5] ; (ii) impairment of arterial baroreceptor sensitivity [6] and vasodilator pathways such as nitric oxide (NO) [7] and prostacyclin [8] , and (iii) deterioration of the oxidative state [6] .
Alternatively, NSAIDs are widely used in inflammation and pain control through mainly the inhibition of cyclooxygenase, the biosynthetic enzyme of prostaglandins [9] . Although the haemodynamic profiling of different NSAIDS is variable, there has been a strong association between NSAIDs and cardiovascular risk and rise in BP [10, 11] . A recent meta-analysis shows that diclofenac has evident vascular risk in patients on at least 4-week treatment period [12] . Diclofenac causes impairment of excitation-contraction coupling in cardiac myocytes via inhibition of L-type calcium channels [13] . On the other hand, reports on the cardiovascular safety profile of selective COX-2 inhibitors such as celecoxib are variable [12, 14, 15] .
Current clinical practices combine NSAIDs and CSA for the treatment of arthritic diseases, for example rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus and chronic polyarthritis [16, 17] . Earlier studies showed a decrease in renal function upon the combined use of CSA and sulindac and naproxen [18] . Diclofenac co-administered with CSA results in raising diclofenac blood level to twice its normal level along with reversible decline in renal function, thus making a potentially detrimental haemodynamic effect of this combination highly likely [19] . That said, little information is available regarding the haemodynamic consequences of concurrent CSA/NSAIDs exposure. In a recent study, we showed that celecoxib abolishes the hypertensive effect of chronically administered CSA in contrast to no effect for non-selective COX-1/COX-2 inhibition by indomethacin [20] . The ameliorating effect of celecoxib on CSA hypertension was accounted for by its ability to reverse the associated increases and decreases in vascular endothelin ETA and ETB receptor expressions, respectively [20] . We also reported that the decreases in COX-2 expression caused by CSA were ameliorated after concurrent treatment with celecoxib but not indomethacin [21, 22] . The negative modulation of the TGF-b1/IL-2 pathway appears to mediate the reversing action of celecoxib on CSA-induced COX-2 up-regulation [21, 22] . Notably, although COX-2 and its prostanoid products are generally considered as pro-inflammatory mediators [23] , evidence suggests that they also exhibit vasodilator and antifibrotic properties [24, 25] . This may explain, at least in part, the key role of increased COX-2 abundance in mediating the favourable effects of celecoxib against the hypertensive and nephrotoxic effects of CSA [20] [21] [22] .
The objective of the current study, which is a follow-up to our recent report that investigated the chronic BP interaction between CSA and NSAIDs [20] , was manifold. Firstly, because our previous study was undertaken in male rats [20] , the current study sought to determine whether this interaction could be reproduced in female rats. Secondly, we investigated whether the preferential counteraction by selective COX-2 inhibitors of CSA hypertension could be seen when drugs were administered acutely. Thirdly, we determined if the lack of effect of indomethacin on CSA hypertension is a drug or class effect. This was verified via exploring the effects of diclofenac, another non-selective COX-1/COX-2 inhibitor, or SC560, a selective COX-1 inhibitor, on CSA hypertension. Fourthly, the study was extended to assess the CSA/NSAIDs interaction on cardiac autonomic and LV functions. All studies were performed in conscious freely moving rats to avoid the confounding effects of anaesthesia on circulatory control [26] .
Materials and Methods
Animals. Female Wistar rats (200-230 g; Faculty of Pharmacy Animal Facility, Alexandria University, Egypt) were used. Experiments were conducted according to a protocol approved by institutional Animal Care and Use Committee and in accordance with standard guidelines on the care and use of the laboratory rat. Animals were housed in plastic cages on wood-chip bedding and held to a 12-hr dark/light cycle. Standard rodent chow and water were provided ad libitum. Rats were frequently (every 3-4 hr) monitored postoperatively during daytimes for signs of weight loss, cyanosis or illness. The majority of operated rats (over 90%) suffered no complications or unexpected death outcomes at any time prior to the experimental end-point. Criteria for euthanasia included weight loss, infection or general weakness. In rare incidences of unexpected severe illness, rats were killed with an overdose of thiopental (100 mg/kg i.v.).
Drugs. Dimethyl sulfoxide (DMSO), polyoxyethylated castor oil (cremophor EL, Sigma-Aldrich, St. Louis, MO, USA), cyclosporine (Sandimmune ampoules; Novartis Pharma AG, Basel, Switzerland), penicillin G benzathine (Pencitard, NCPC North Best Co., Cairo Egypt), povidone-iodine solution (Betadine, Nile Pharmaceutical Co.,
[trifluoromethyl]-1Hpyrazole; Tocris Bioscience, Bristol, UK) and thiopental (Biochemie GmbH, Vienna, Austria) were purchased from commercial vendors. Diclofenac potassium and celecoxib were gifts from the European Egyptian Pharmaceutical Industries (Alexandria, Egypt). Each 1 ml of CSA ampoule contained 50 mg of CSA, 650 mg cremophor and 0.33 ml ethyl alcohol. Ampoules were diluted five times with saline and used for i.v. administration at a dose of 10 mg/ml/kg. Diclofenac, celecoxib or SC560 was dissolved in 40% DMSO and kept in glass vials wrapped in aluminium foil to be protected from light.
Intravascular cannulation. The method described in our previous studies was adopted [27, 28] . In brief, rats were anaesthetized with thiopental (50 mg/kg, i.p.). Polyethylene catheters (each consisted of 5-cm PE-10 tubing tightly bonded to 15-cm PE-50 tubing) were placed in the abdominal aorta and vena cava via the femoral artery and vein, for measurement of BP and i.v. drug administration, respectively. Catheters were tunnelled subcutaneously, exteriorized at the back of the neck between the scapulae, flushed with heparin (0.2 ml, 100 U/ml) and plugged by stainless steel pins. Each rat received an intramuscular injection of 60,000 U of penicillin G benzathine in an aqueous suspension and was housed in a separate cage. Experiments started 2 days after the surgery on freely moving conscious rats. On the day of the experiment, the arterial catheter was connected to a BP transducer (model P23XL; Astro-Med, West Warwick, RI, USA) that was attached through MLAC11 Grass adapter cable to a computerized data acquisition system with LabChart-7 pro software (Power Lab 4/35, model ML866/P; AD Instruments Pty Ltd., Castle Hill, Australia). The HR was computed from BP waveforms and displayed on another channel of the recording system.
Time-domain analysis of HRV. Two time-domain measures of the cardiac autonomic activity were employed, the standard deviation of beat-to-beat intervals (SDNN) and the root mean square of successive beat-to-beat differences in RR interval durations (rMSSD) [29, 30] . The RR intervals were computed as the reciprocal of HR in ms. SDNN is comparable to the total power of the spectrum of RR variability, which measures the overall autonomic balance of the heart. rMSSD is largely validated as a measure of the parasympathetic input to the heart and, therefore, correlates with the high-frequency power of the spectrum [31] SDNN and rMSSD were measured before (baseline) and at 15-min. intervals after drug treatments. For each time point, the 5-min. values of each variable were averaged.
Frequency-domain analysis of HRV. Spectral haemodynamic fluctuations, quantitative indices of cardiac autonomic control [31, 32] , were used to reflect changes in sympathetic and vagal out-flows. Heart rate variability (HRV) was analysed in the frequency domain using FFT algorithms of RR data series. The FFT algorithm for direct transformation of data points into power spectral density graphs was used. Data were interpolated to obtain equally spaced samples with an effective sampling frequency of 10 Hz (0.1 sec.). A second-order interpolation was employed to fit a smooth curve to the existing data points and produce a smoother visual representation of data. The Table 1 . Baseline values of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), pulse pressure index (PPI), myocardial contractility (dP/dt max ) and isovolumic relaxation constant (Tau). Protocols and experimental groups.
Interaction of CSA with diclofenac or celecoxib. Six groups of conscious female rats (n = 8 each) pre-instrumented 2 days earlier with femoral indwelling catheters were employed to determine the effect of post-treatment with diclofenac or celecoxib on CSA haemodynamics. On the experiment day, the arterial catheter was connected to a pressure transducer and Power Lab data acquisition system for haemodynamic measurements, and a stabilization period of 30 min. was allowed. Rats were randomly assigned to receive one of the following i.v. regimens: (i) vehicles (cremophor + DMSO), (ii) cremophor + diclofenac (10 mg/kg), (iii) cremophor + celecoxib (10 mg/kg), (iv) CSA (10 mg/kg) + DMSO, (v) CSA + diclofenac or (vi) CSA + celecoxib. The 10 mg/kg dose of diclofenac or celecoxib was employed here because it has been used in previous studies and Table 2 . Baseline values of time-domain (standard deviation of beat-to-beat intervals, SDNN; and root mean square of successive beat-to-beat differences in R-R intervals, rMSSD) and frequency-domain (total power, TP; low frequency, LF; high frequency, HF; and LF/HF ratio) indices of heart rate variability. shown to possess anti-inflammatory activity [33, 34] . Moreover, based on published recommendation concerning dose conversion between human beings and rats [35] , this dose of either NSAIDs corresponds to a human dose of 1.3 mg/kg (i.e. 100 mg per person of 70 kg body-weight). Drugs were infused slowly over 2-3 min., and 10 min. was allowed between the two successive treatments of each regimen. The cremophor solution was prepared by mixing 650 mg cremophor, 0.33 ml ethyl alcohol and saline up to 1 ml. This solution was further diluted five times with saline and administered intravenously to rats at a dose of 1 ml/kg. Haemodynamic monitoring continued for 90 min. after the second drug treatment of each regimen. Systolic BP (SBP), diastolic BP (DBP), HR and pulse pressure index (PPI, pulse pressure/SBP) were measured. The isovolumic relaxation time constant (Tau), which represents the exponential decay of the ventricular pressure during isovolumic relaxation [36] , and the maximum rate of rise of BP waves (+dP/dt max ), index of LV contractility [26] , were computed by LabChart-7 pro software. Parameters were measured before (baseline) and then at 10-min. intervals after drug administration. The time-and frequency-domain indices of HRV were also computed as detailed above.
Interaction of CSA with SC560. Two groups of conscious female rats (n = 8 each) were used to investigate the effect of selective COX-1 inhibition on the cardiovascular effects of CSA. Rats were treated with cremophor plus SC560 (selective COX-1 inhibitor, 10 mg/kg) or CSA (10 mg/kg) plus SC560. Haemodynamic monitoring continued for 90 min. after the second drug treatment. Drugs were administered intravenously, and haemodynamic variables were computed as described in the previous experiment.
Statistical analysis. Values were expressed as means AE S.E.M. The analysis of variance (ANOVA) followed by Bonferroni post hoc analysis was used for multiple comparisons. The analysis was performed using GraphPad Prism, software release 3.02. Probability levels <0.05 were considered significant.
Results
Haemodynamic interaction between CSA and celecoxib or diclofenac.
The baseline values of all variables in different rat groups prior to drug administration were not statistically different (tables 1 and 2). the study ( fig. 1B-D) . The combined treatment of rats with CSA and diclofenac elicited additive increases in BP; the increases in SBP caused by the combined regimen achieved statistical significance compared with individual treatments at almost all times points ( fig. 1B) . By contrast, i.v. administration of the selective COX-2 inhibitor celecoxib (10 mg/kg) failed to alter SBP and DBP on its own and remarkably abolished the increases in both pressure variables caused by concurrent CSA administration ( fig. 1A-C) .
The pressor effect of CSA in female rats was associated with significant decreases in PPI ( fig. 2A,B) and HR (fig. 2C,  D) . These parameters were not altered in rats treated with celecoxib or diclofenac, except for a significant reduction in HR caused by diclofenac compared with control values. On the other hand, the decreases in PPI and increases in HR caused by CSA were abolished and preserved in rats treated concurrently with celecoxib and diclofenac, respectively ( fig. 2) .
LV interaction between CSA and celecoxib or diclofenac. The effects of CSA, NSAIDs and their combination on LV function were assessed. CSA treatment increased LV contractility demonstrated by an increase in the maximum positive derivative of LV pressure (dP/dt max ) ( fig. 3A,B) . Neither diclofenac nor celecoxib affected LV contractility when used alone. However, upon combination with CSA, celecoxib reduced the increase in dP/dt max brought about by CSA treatment to values similar to that of vehicle-treated rats. In rats treated with CSA/diclofenac combination, dP/dt max was significantly increased to levels that mimicked those caused by CSA alone (fig. 3A,B) .
On the other hand, the isovolumic relaxation constant (Tau), a direct measure of diastolic function that is independent of pre-load or post-load, was significantly increased after CSA treatment indicating impaired ventricular relaxation ( fig. 3C,  D) . Tau was not affected by either NSAID treatment. Yet, similar to the changes in dP/dt max , concurrent treatment with celecoxib normalized myocardial relaxation and reversed the CSA-induced Tau increases. Such a reduction was not observed in the diclofenac/CSA combination where Tau values remained elevated ( fig. 3C,D) . fig. 4 . CSA significantly increased both SDNN and rMSSD values, which are consistent with increased global autonomic and parasympathetic activities, respectively. Neither diclofenac nor celecoxib affected these parameters when used alone. In accordance with the previous effects on BP, HR and LV function, celecoxib ameliorated the augmented SDNN and rMSSD values produced by CSA, yet these variables remained elevated in the diclofenac/CSA-treated rats (fig. 4) .
Similar observations were noted regarding the influences on frequency-domain parameters of HRV. CSA increased the spectral densities in the LF and HF ranges of HRV along with an increase in total power (figs 5 and 6). The LF/HF ratio was significantly decreased by CSA, denoting cardiac parasympathetic dominance. Diclofenac treatment augmented HF and maintained the CSA influences on all parameters when given in combination ( fig. 6B) . Celecoxib, on the other hand, showed no effect on the frequency-domain parameters on its own and significantly reduced the CSA-induced increases in total power, HF and LF. Celecoxib also caused significant increases in the CSA-evoked reductions in the sympathovagal balance (LF/HF ratio) ( fig. 6C ).
Interaction between CSA and SC560. The effects of selective COX-1 inhibition by SC560 on CSA haemodynamic and HRV parameters were examined in conscious female rats. Similar to the results obtained with diclofenac, the treatment with SC560 alone produced an increase in SBP and DBP. In addition, the co-treatment of rats with SC560 resulted in further augmentation of the pressor effect caused by CSA ( fig. 7A,B) . Also, the reduction in LF/HF ratio caused by CSA was maintained upon concurrent treatment with SC560 ( fig. 7C) . Regarding left ventricular function, SC560 increased dP/dtmax in a manner similar to diclofenac when administered alone and maintained the CSAinduced increase in this parameter when given in combination ( fig. 7D ).
Discussion
Previous reports from our laboratory demonstrated a protective effect for celecoxib, but not indomethacin, against the hypertensive and nephrotoxic actions induced by chronic CSA administration in male rats via the modulation of endothelin receptor expression [20, 21] . The aim of the current study was to clarify the acute haemodynamic interaction between CSA and NSAIDs with different COX selectivity in female rats. The study was extended to investigate the impact of this interaction on myocardial autonomic control and LV function. Novel findings of the present study include: (i) the pressor effect of i.v. CSA was abrogated after selective COX-2 inhibition (celecoxib) and potentiated after non-selective COX-1/COX-2 inhibition (diclofenac); (ii) the CSA-induced alterations in myocardial function, which involved rises in dP/dt max , Tau, and time and frequency domains of HRV and shifts in cardiac autonomic balance towards parasympathetic dominance, disappeared upon concurrent treatment with celecoxib but not diclofenac; and (iii) the failure of diclofenac to reverse the detrimental haemodynamic and autonomic actions of CSA was echoed after replacing diclofenac with SC560, a selective COX-1 inhibitor. The data suggest favourable influences for the selective COX-2 inhibitor celecoxib in managing the negative haemodynamic and myocardial action of acutely administered CSA, whereas COX-1 inhibition produced by diclofenac or SC560 appears to exacerbate or at least to preserve the injurious cardiovascular effects of CSA.
The BP elevation caused by acute CSA is consistent with previous reports regarding CSA-induced hypertension [1, 3, 6] .
The pressor effect of CSA was accompanied by an increase in arterial compliance as demonstrated by the associated decreases in PPI (pulse pressure/systolic pressure). The latter was originally derived by Peng-Lin and Yue-Chun [37] and suggested to provide a more powerful predictor of heart disease and compromised arterial compliance than pulse pressure. Moreover, the fall in HR seen in CSA-treated rats is consistent with the study by Shaltout and Abdel-Rahman [38] , which attributed the negative chronotropic effect of CSA to arterial baroreceptor loading secondary to the rise in BP. In contrast to the bradycardic effect caused by CSA in this and previous studies, HR is increased by acutely administered CSA in some studies [39] . Although the reason(s) for the discrepant HR effects of CSA is not fully understood, one possible factor might be the difference in the CSA regimen. A lower bolus dose of CSA (5.9 mg/kg) was employed in the study by Gardiner et al. [38, 39] compared to slow infusion of 10 mg/kg in the present study and 15 mg/kg in the study by Shaltout and Abdel-Rahman [38, 39] . More studies are needed to understand the regimen dependency of the chronotropic response elicited by CSA.
In a previous study performed in male rats, we found that the pressor effect of CSA is abolished upon simultaneous administration of the selective COX-2 inhibitor celecoxib, whereas non-selective COX inhibition by indomethacin was without effect [20] . The current study provides more insights into this clinically relevant interaction by studying the sex and drug class dependencies of the CSA/NSAIDs haemodynamic interaction. Several important observations are reported here along this context. Firstly, similar to its effects in male rats [20] , CSA elicits no hypertension in female rats treated concurrently with celecoxib. Secondly, the preservation of the hypertensive effect of CSA in rats treated with the non-selective COX inhibitor indomethacin [20] was replicated in the present study when diclofenac, another non-selective NSAID, was employed. In fact, as illustrated in fig. 1 , BP elevations caused by the combined use of CSA and diclofenac were significantly greater than the pressor responses elicited by individual drug treatments. Together, findings of the current and previous [20] studies indicate that while CSA hypertension is ameliorated by celecoxib in a sex-independent fashion, it remains unaltered (male rats) [20] or intensifies (female rats, this study) after non-selective COX inhibition.
To complement and better comprehend the CSA/NSAIDs haemodynamic interaction, we examined the effects of these intervening molecules on LV functions and cardiac autonomic control. The increase caused by acutely administered CSA in dP/dt max , a measure of cardiac contractility and LV systolic function [32, 40] is consistent with reported studies regarding the ability of acute CSA regimens to facilitate myocardial contractility, cardiac output and sympathetic activity [41, 42] . Obviously, these changes in LV function are important contributors to the CSA-evoked hypertension [4, 43] . This view receives more support from our findings that like the changes in the BP profile, the increases in dP/dt max caused by CSA disappeared in rats treated concomitantly with celecoxib but not diclofenac.
Heart rate variability analysis is a non-pharmacological approach that is traditionally used to provide insight into cardiac autonomic control [44] . Consistent with our previous report [29] , CSA significantly increased time-domain indices of HRV (SDNN and rMSSD). These findings are bolstered by the current frequency-domain analysis data that CSA increased the spectral densities in the LF and HF ranges and reduced the LF/HF ratio, denoting increased sympathetic and parasympathetic activities with a shift in cardiac sympathovagal balance towards parasympathetic dominance. The heightened parasympathetic control of the heart might explain the bradycardic effect of CSA and associated diastolic dysfunction demonstrated by the increases in cardiac isovolumic relaxation constant (Τau). The latter effects together with the improved arterial compliance (reduced PPI) may serve to counterbalance the CSA-evoked increments in BP and myocardial contractility. Interestingly, the alterations caused by CSA in time-and frequency-domain measures of HRV, sympathovagal balance and diastolic function were all reversed upon concurrent administration of celecoxib, thereby reinforcing the preferential ability of COX-2 inhibition in normalizing cardiovascular abnormalities induced by CSA in female rats.
That said, accumulated evidence that questions the cardiovascular safety of selective COX-2 inhibitors due probably to the suppression of prostacyclin synthesis cannot be overlooked [45] . The VIGOR (Vioxx GI Outcomes Research) study group in 2000 highlights the increased incidence of cardiovascular risk in patients on rofecoxib therapy, which has led ultimately to its recall by FDA in 2004 [46] . Notably, the pharmacological profiling for members of the coxib family is quite variable. Celecoxib has been shown to lower BP [47] mitigate oxidative autonomic dysfunction [48] , and cause vasodilation through the facilitation of NO/cGMP signalling and inhibition of phosphodiesterase-5 [49] . Celecoxib also elicits a potent vasodilator capacity in human mesenteric arteries [50] . Reports from our laboratory and others highlighted favourable effects for COX-2 inhibition on myocardial ischaemia [51, 52] and vasculotoxicity [20, 21] .
By the same token, the exaggeration of CSA hypertension and the preservation of concomitant cardiac autonomic and LV influences in diclofenac-treated rats may suggest that the advantageous effects of COX-2 inhibition might be compromised by the paralleled inhibition of COX-1. This postulate prompted us to investigate whether the adverse effects of diclofenac on CSA haemodynamics could be replicated after selective COX-1 inhibition by SC560. This assumption was verified by the present findings that SC560, like diclofenac, increased BP when used alone and potentiated the pressor action of concomitantly administered CSA. Further, the increases and decreases caused by CSA in myocardial contractility (dP/dt max ) and sympathovagal balance (LF/HF ratio), respectively, were maintained in rats treated concurrently with SC560. The resemblance in the way by which diclofenac and SC560 altered the cardiovascular effects of CSA highlights the importance of COX-1 inhibition, at least partly, in these interactions.
It is imperative to comment on the clinical relevance and potential limitations of the current study. Based on our findings, the combined use of selective COX-2, rather than the non-selective COX1/COX2, inhibitors along with CSA might be more advantageous for the management of arthritic conditions [16, 17] . Earlier studies have also shown that COX-2 inhibition by celecoxib boosts immunotherapy efficacy via the reduction in suppressive immune cells [53] . Moreover, COX-2 inhibition suppresses graft rejection and improves the survivability of cardiac allografts [54] . By contrast, exaggerated kidney injury in solid organ transplant recipients [55] and rats [21] due to the concurrent exposure to CSA and NSAIDs has been reported. More studies are needed to assess more accurately the benefit/risk ratio of CSA/NSAIDs regimens.
The present study suffers two limitations. Firstly, experiments were performed in randomly cycling rats and no efforts were made to determine whether the CSA/NSAIDs interaction could be influenced by the oestrus cycle phase. The impact of cyclic fluctuations in gonadal hormonal level, a key modulator of haemodynamics [56] [57] [58] , on the measured variables cannot be overlooked. Secondly, because healthy animals were employed in the present study, it is not clear whether similar interactions would develop in pathologies that necessitate the concurrent use of CSA and NSAIDs. With the idea in mind that the inflammation state positively correlates with cardiovascular morbidity and mortality [59] , it is possible that the clinical use of CSA/NSAIDs therapy might be accompanied by more serious cardiovascular complications.
In conclusion, the current communication is the first to report on the acute haemodynamic interaction between NSAIDs of different COX-1/COX-2 selectivities with CSA and its implication on the myocardial autonomic balance and LV function in female rats. The data suggest variable and perhaps directionally opposite contributions for the two COX isoforms in the CSA/NSAIDs interaction. Selective COX-2 inhibition by celecoxib abolished the pressor response and the associated alterations in LV systolic and diastolic functions and cardiac autonomic control. By contrast, diclofenac (nonselective COX-1/2 inhibitor) or SC560 (selective COX-1 inhibitor) potentiated the pressor action of CSA and failed to counteract its detrimental effects on LV and autonomic functions. More studies are needed to delineate biochemical and molecular bases of these interactions.
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